884 related articles for article (PubMed ID: 19661383)
1. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.
Yun J; Rago C; Cheong I; Pagliarini R; Angenendt P; Rajagopalan H; Schmidt K; Willson JK; Markowitz S; Zhou S; Diaz LA; Velculescu VE; Lengauer C; Kinzler KW; Vogelstein B; Papadopoulos N
Science; 2009 Sep; 325(5947):1555-9. PubMed ID: 19661383
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.
Hutton JE; Wang X; Zimmerman LJ; Slebos RJ; Trenary IA; Young JD; Li M; Liebler DC
Mol Cell Proteomics; 2016 Sep; 15(9):2924-38. PubMed ID: 27340238
[TBL] [Abstract][Full Text] [Related]
3. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
[TBL] [Abstract][Full Text] [Related]
4. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
5. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
[TBL] [Abstract][Full Text] [Related]
6. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
7. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
8. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
9. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
10. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
12. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
[TBL] [Abstract][Full Text] [Related]
14. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
16. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
Yeh JJ; Routh ED; Rubinas T; Peacock J; Martin TD; Shen XJ; Sandler RS; Kim HJ; Keku TO; Der CJ
Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
[TBL] [Abstract][Full Text] [Related]
17. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
18. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells.
Patankar M; Eskelinen S; Tuomisto A; Mäkinen MJ; Karttunen TJ
Mol Med Rep; 2019 Nov; 20(5):4634-4644. PubMed ID: 31545494
[TBL] [Abstract][Full Text] [Related]
20. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
